spacer
home > ebr > summer 2019 > the renaissance of microbial fermentation
PUBLICATIONS
European Biopharmaceutical Review

The Renaissance of Microbial Fermentation

Initially, many smaller biologic drug substances − including recombinant proteins and peptides − were produced via microbial fermentation. However, with the advent of cell culture systems, interest shifted to mammalian systems to produce larger proteins and antibodies. Now, the introduction of smaller, complex next-generation molecules, such as bioconjugates, antibody fragments, and other scaffolds, are once again driving interest in fermentation as an effective manufacturing platform.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Vladas Bumelis is the founder of Northway Biotechpharma and Chairman of the companys Board of Directors and Advisory Board. He has extensive experience in the pharma and biotechnology industries, having previously served as General Manager of Teva Pharmaceutical Industries, Chairman of the Board for Biofa and Biotechna, and Chairman of the Board and General Manager of the Institute of Applied Enzymology in Lithuania. In 2004, Vladas received the Science Award of Lithuania in recognition of his achievements in the development and production of recombinant proteins. He has a PhD and MSc in chemistry, as well as a PhD in biotechnology, from Vilnius University, Lithuania.
spacer
Dr Vladas Bumelis
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Entry now open for the PPMA Group Industry Awards 2019

The 2019 PPMA Group Industry Awards will be held at the National Conference Centre (NEC), Birmingham, on the evening of the first day of the PPMA Total Show 2019 Tuesday, 1 October 2019. 
More info >>

White Papers

The Rare Disease Patients Experience

When planning a clinical trial for a rare disease, it is important to have a holistic understanding of your patient population. You want to be aware of where your patients are coming from, and what it is like to walk in their shoes. These patients need your trial just as much as you need them; even from the earliest stages, conceptualize your rare disease trial as an altruistic relationship between the patient population and your study.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement